Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs
Author(s) -
Miguel Fribourg,
José L. Moreno,
Terrell Holloway,
Davide Provasi,
Lia Baki,
Rahul Mahajan,
Chang Gyu Park,
Scott K. Adney,
Candice N. Hatcher,
José M. Eltit,
Jeffrey Ruta,
Laura Albizu,
Zheng Li,
Adrienne Umali,
Jihyun Shim,
A Fabiato,
Alexander D. MacKerell,
Vladimír Březina,
Stuart C. Sealfon,
Marta Filizola,
Javier GonzálezMaeso,
Diomedes E. Logothetis
Publication year - 2011
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2011.09.055
Subject(s) - biology , metabotropic glutamate receptor 2 , serotonergic , heterotrimeric g protein , antipsychotic , neuroscience , pharmacology , g protein coupled receptor , metabotropic receptor , signal transduction , g protein , receptor , microbiology and biotechnology , glutamate receptor , serotonin , schizophrenia (object oriented programming) , biochemistry , medicine , psychiatry
Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT(2A) G protein-coupled receptor (GPCR), the 2AR, which signals via a G(q) heterotrimeric G protein. The closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 2AR function, but they lack comparable neuropsychological effects. Why some but not all 2AR inhibitors exhibit antipsychotic properties remains unresolved. We now show that a heteromeric complex between the 2AR and the G(i)-linked GPCR, metabotropic glutamate 2 receptor (mGluR2), integrates ligand input, modulating signaling output and behavioral changes. Serotonergic and glutamatergic drugs bind the mGluR2/2AR heterocomplex, which then balances Gi- and Gq-dependent signaling. We find that the mGluR2/2AR-mediated changes in Gi and Gq activity predict the psychoactive behavioral effects of a variety of pharmocological compounds. These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom